Prostate Cancer Treatment Option

 Prostate Cancer Treatment Option

Cancer Man Man Prostate Surviving
Cancer Diagnosis More Prostate Test
Cancer Hormone Prostate Treatment
Cancer In Ontario Prostate Treatment
Picture Of Prostate Cancer
Cancer Prostate Radiation Seed
Cancer Prostate Masturbation
Prostate Cancer Risk Factor
Alternative Prostate Cancer Treatment
Cancer Late Prostate Stage
Cancer Prostate Radiation Therapy
Prostate Cancer Cure And Treatment
Treatment Post Operative Prostate Cancer
Prostate Cancer Cure
Cancer Florida Prostate Treatment
Prostate Cancer Chemotherapy
Cancer Effects Prostate Radiation Side
Early Symptom Prostate Cancer
Prostate Cancer Bone Metastasis
Prostate Cancer Prognosis
Prostate Cancer Sex
Prostate Cancer Diet
Prostate Cancer Hormone Therapy
Prostate Cancer Question And Answer
3 Cancer Prostate Stage
Lycopene Prostate Cancer
Alternative Cancer Localized Prostate Treatment
Prostate Cancer Psa Level
Alternative Cancer Medicine Prostate
Cancer Cryosurgery Prostate
Prostate Cancer Impotence
Prostate Cancer Information
Prostate Cancer Warning Sign
Prostate Cancer Brachytherapy



 

 

Olmert says he has prostate cancer

Prostate cancer and treatment options are in public focus as Israeli PM Olmert reveals that he has prostate cancer, but will stay on the post.

Israel's Prime Minister Ehud Olmert said on Monday he had prostate cancer, but that it was not life-threatening, and he would continue to perform his duties.

"I have a tumor of the prostate in the very early stages... It is a minor tumor that can be surgically removed. This is not life-threatening and is treatable," he told a news conference.

Olmert said the tumor was revealed during a routine medical examination, and it will not require radiation treatment or chemotherapy

The consulting physicians told the news conference the tumor did not require urgent surgery, and that in such cases surgery to remove the tumor was usually performed no earlier than six weeks after the initial biopsy.


Interim Analysis Supports Continuation Of Cell Genesys' VITAL-1 Phase ...

Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue. This event-driven interim analysis was designed to determine whether the study should continue to completion and took place in the time frame originally estimated. As is customary to preserve study blinding, the IDMC provided no information to the company other than the recommendation to continue the trial.

"The IDMC's recommendation to continue with the VITAL-1 trial represents an important step forward in the Phase 3 development of GVAX immunotherapy for prostate cancer and in our effort to make this product available as a new treatment option for men with prostate cancer," stated Robert Dow, MBChB, chief medical officer of Cell Genesys.


Philadelphia sports writers honor runner

Breast cancer couldn't stop Lois Gilmore from running. Neither could a stroke five years ago.

Through it all, the 77-year-old Gilmore, from Janesville, Wis., has continued to run competitively most weekends, even when impaired vision from the stroke left her running into the occasional road sign or fence post.

Gilmore would gather herself up, brush herself off, point herself toward the finish line, and take off again.

"I finished every race I fell down in," Gilmore said yesterday with a hint of pride.

Her determination has paid off. In 2007, for the second straight year, Gilmore competed in 64 races, most of them 5- to 15-kilometer runs, and ranked as the No. 1 runner in the country among runners 75 and older. USA Track and Field named her its 2007 Masters Athlete of the Year.



 

 

 

Link to us - Contact us